HC Wainwright Expects Higher Earnings for Arcus Biosciences

Arcus Biosciences, Inc. (NYSE:RCUS) – Equities research analysts at HC Wainwright raised their Q2 2026 EPS estimates for Arcus Biosciences in a report issued on Wednesday, May 6th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($1.04) per share for the quarter, up from their prior forecast of ($1.05). HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q3 2026 earnings at ($1.07) EPS, Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($4.88) EPS, FY2027 earnings at ($3.85) EPS, FY2028 earnings at ($2.32) EPS, FY2029 earnings at ($0.81) EPS and FY2030 earnings at $0.44 EPS.

A number of other research analysts have also recently issued reports on the stock. Wall Street Zen raised shares of Arcus Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $20.00 price target (down from $23.00) on shares of Arcus Biosciences in a report on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a report on Monday, April 20th. Citigroup raised their price target on shares of Arcus Biosciences from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, Truist Financial raised shares of Arcus Biosciences to a “strong-buy” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.11.

Arcus Biosciences Trading Down 4.6%

NYSE:RCUS opened at $24.80 on Friday. Arcus Biosciences has a 52 week low of $7.72 and a 52 week high of $28.72. The firm has a 50 day moving average of $22.93 and a 200 day moving average of $22.10. The company has a quick ratio of 4.36, a current ratio of 4.04 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $3.12 billion, a price-to-earnings ratio of -7.80 and a beta of 0.87.

Arcus Biosciences (NYSE:RCUS) last posted its earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. The firm had revenue of $17.00 million for the quarter, compared to analysts’ expectations of $29.49 million. During the same period in the previous year, the company earned ($1.14) EPS. The company’s revenue was down 39.3% on a year-over-year basis.

Institutional Trading of Arcus Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Hantz Financial Services Inc. increased its stake in shares of Arcus Biosciences by 121.9% in the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock worth $38,000 after acquiring an additional 881 shares during the period. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Arcus Biosciences in the fourth quarter worth $39,000. KBC Group NV acquired a new stake in shares of Arcus Biosciences in the first quarter worth $50,000. SBI Securities Co. Ltd. increased its stake in shares of Arcus Biosciences by 13,547.6% in the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock worth $39,000 after acquiring an additional 2,845 shares during the period. Finally, GAMMA Investing LLC increased its stake in shares of Arcus Biosciences by 17.5% in the fourth quarter. GAMMA Investing LLC now owns 3,230 shares of the company’s stock worth $77,000 after acquiring an additional 482 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.